Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
Conditions
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
Trial Timeline
Sep 29, 2020 → Jul 22, 2024
NCT ID
NCT04245085About Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed is a phase 2 stage product being developed by Roche for EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT04245085. Target conditions include EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04245085 | Phase 2 | Completed |